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We quantified rates of hepatic regeneration and functional recovery for 6 months after right
hepatic lobectomy in living donors for liver transplantation.
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Twelve donors were studied at baseline; eight retested at (mean±SD) 11±3 days (T1), 10 at 91±9
days (T2), and 10 at 185±17 days (T3) after donation. Liver and spleen volumes were measured
by computed tomography (CT) and single photon emission computed tomography (SPECT).
Hepatic metabolism was assessed from caffeine and erythromycin, and hepatic blood flow from
cholates, galactose, and perfused hepatic mass (PHM, by SPECT).
Regeneration rates (mL liver per kg body weight per day) were 0.60±0.22 from baseline to T1,
0.05±0.02 from T1 to T2, 0.01±0.01 from T2 to T3 by CT, 0.54±0.20, 0.04±0.01 and 0.01±0.02
by SPECT. At T3, liver volume was 84±7% of baseline by CT and 92±13% by SPECT. Changes
in hepatic metabolism did not achieve statistical significance. At T1, unadjusted clearance ratios
relative to baseline were 0.75±0.07 for intravenous cholate (p=0.0001), 0.88±0.15 for galactose
(p=0.0681), 0.84±0.08 (p=0.002) for PHM, and 0.83±0.19 (p=0.056) for estimated hepatic blood
flow. These ratios approached 1.00 by T3. At T1, ratios adjusted per L liver were 20%-50%
greater than baseline and trended toward baseline by T3. Several findings were consistent with
alteration of the portal circulation: increased cholate shunt, increased spleen volume, decreased
platelet count, and decreased clearance of orally-administered cholate.
During the first 2 weeks after donation, hepatic regeneration is rapid and accounts for nearly two-
thirds of total regeneration. Increases in hepatic blood flow and uptake of cholate characterize the
early phase of regeneration. Right lobe donation alters the portal circulation of living donors, but
long-term clinical consequences, if any, are unknown.
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Donor safety and outcome are the chief concerns of programs performing living donor liver
transplantation (1,2). For adult recipients, a right lobe graft may be preferred over left lobe
grafts due to the larger hepatic mass and anatomic orientation of vascular and biliary
structures. For donors, a consequence of donating the right lobe graft is a relatively small
remnant of residual liver from which to regenerate their liver mass. Even though hepatic
regeneration permits donors to tolerate these resections, typically uneventfully, transient
hepatic impairment is common, and hepatic failure, although rare, has been described (1-3).
In animal models, hepatic regeneration after resection of an otherwise normal liver is rapid,
and usually complete within a few weeks (4,5). In these models, survival is linked to rate
and completeness of regeneration and restoration of hepatic function.
Less is known about hepatic regeneration, hepatic function, and clinical outcomes in
humans. Humar and colleagues measured liver volumes by computed tomography (CT) at 3
months post-donation and found that donor liver volume was 78.6% of ideal, whereas
recipient liver volume was 103.9% of ideal (6). Nadalin measured the volumes of donor
remnants by magnetic resonance imaging (MRI) and found that remnant volumes were 39%
of baseline immediately after resection, increased to 77% by 3 months, and were 83% of
baseline at 1 year after donation (7). Pomfreit and colleagues performed CT studies at
baseline and 1 week and 1, 3, 6, and 12 months post-donation (8). By 1 year, liver volume
was 83.3% of baseline, and female donors had significantly less regeneration compared with
male donors (79.8 vs. 85.6%, p=0.01). These studies suggest that the regeneration of donor
remnants is incomplete.
Some studies have also evaluated the impact of donation on hepatic function. Nadalin
studied galactose elimination capacity (GEC) and found that unadjusted GEC had declined
50% by day 10, but had returned to baseline at subsequent time points (7). GEC adjusted for
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volume of remnant liver declined by less than 25% by day 10, was increased above baseline
at days 90 and 180, and returned to baseline by day 360. Jochum (9) had results similar to
Nadalin – GEC, expressed per kg body weight, was 50% lower than baseline at day 10 and
nearly at baseline by day 90. Jochum also observed that indocyanine green (ICG) half-life
increased and lidocaine half-life was not significantly altered (9). Neither study measured a
broad array of liver functions nor did they examine the relationships of function to
regeneration.
In our study, we measured multiple hepatic functions, hepatic blood flow, total liver and
perfused liver volumes, and related these results to regeneration of the remnant left lobe
during the first 6 months after right lobe donation.
PATIENTS AND METHODS
Patients
Donors were approached for participation in this study only after they had undergone a full
evaluation for living donor liver transplantation, were approved by the Selection Committee
for liver transplantation, and the date of the operation was scheduled. Donors were recruited
from two Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL)
clinical centers – University of Colorado, Denver and University of California, San
Francisco.
The protocol was approved by the Institutional Review Boards at the participating
institutions, and all subjects provided written informed consent for both the main A2ALL
study and this A2ALL-approved ancillary study.
Procedures, Test Compounds, and Analytical Methods
Participants maintained a caffeine-free, grapefruit juice-free, and alcohol-free diet for 3 days
and were studied in the morning after an overnight fast in the General Clinical Research
Centers (GCRC) of the participating centers. An indwelling intravenous 20-gauge catheter
was placed for administration of test compounds and sampling blood. Patients were supine
during the study and minimized their activity.
Hepatic metabolism was quantified using erythromycin (10) and caffeine (11) as test
compounds.
Erythromycin breath test (EBT)—Three μCi of [14C-N-methyl] erythromycin
(Metabolic Solutions Inc, Nashua, NH, product #: 02410806, IND: 31,760) was
administered intravenously with a bolus injection followed by a 10 ml normal saline flush.
Breath samples for measurement of 14CO2 generated from the hepatic metabolism of
erythromycin were collected at baseline and 20 minutes after dose administration using a T-
tube apparatus, capture solution, and indicator dye (12). 14CO2 was quantified by
radioscintigraphy and percentage of erythromycin metabolized per hour determined.
Caffeine elimination rate (Caff kelim) and clearance (Caff Cl)—Caffeine, 300 mg
(Ruger Chemical Co., Irvington, NJ, product number 0072-5, IND 65,175), was
administered orally and its hepatic metabolism determined from clearance measured by
high-performance liquid chromatography (HPLC) of saliva samples obtained at 2, 4, 8, and
12 hours after dosing. Volume of distribution (Vd) and kelim were determined by linear
regression of loge concentration versus time and Cl was the product of Vd multiplied by
kelim.
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The hepatic circulation was quantified using test compounds with flow-dependent, high
first-pass hepatic extraction (galactose (13), cholates (14-17), 99mTc-cis-sulfur colloid
(15-18).
Galactose elimination capacity (GEC)—Galactose, 30 g of low endotoxin D-galactose
(Pfanstiehl Laboratories, Inc., Waukegan, IL, product number G-105-1, IND 65107), in 100
mL sterile water was administered intravenously over 5 minutes. Blood samples were
obtained at baseline and 20, 40, 60, and 80 minutes after dosing and galactose concentration
quantified by spectrophotometry using a standardized kit (Lactose/D-galactose kit,
Boehringer Mannheim Cat. No. 176 303). GEC is the slope from the linear regression of
concentration versus time.
Cholate clearances (CA Cl) and shunt (CA shunt)—Dual isotopes of cholate were
simultaneously administered in anionic form in bicarbonate solutions, one orally and the
other intravenously (14-17). The oral solution contained 40 mg of 2,2,4,4-2H cholate (CDN
Isotopes Inc. Quebec Canada, product # D-2452, studied under IND 65123) plus 600 mg
NaHCO3 in apple or grape juice. The intravenous solution contained 20 mg 24-13C cholate
(CDN Isotopes Inc. Quebec Canada, product # C-3448, studied under IND 65121) dissolved
in 5 mL of USP grade NaHCO3, 1meq/mL (Baxter HealthCare, Tarrytown, NY). This
solution was mixed with 5 mL of USP grade 25% human serum albumin (Bayer HealthCare
Tarrytown, NY 10591 NDC# 0026-0692-16) and administered via antecubital vein over 1
minute. Blood samples were obtained at baseline and at 5, 20, 45, 60, and 90 minutes after
dosing (14) and cholate isotopes quantified by LC/MS. CA Cloral and CA Cliv were
calculated from dose (40 mg oral or 20 mg intravenous) divided by area under the
concentration versus time curves for each isotope (mg*min/mL) and normalized for body
weight (kg), and CA shunt was the ratio of clearances of the intravenously to orally-
administered isotopes. Estimated hepatic blood flow was calculated from the equation, CA
Cliv/((1-shunt/100)*(1-hematocrit)). An example of a pair of studies from one donor of dual
cholate clearance studies prior to and after donation is shown in Figure 1.
SPECT liver-spleen scan—After completion of blood sampling for the galactose and
cholate tests, patients ingested a standard meal and 375 ml Ensure (Abbott Laboratories,
Abbott Park, IL) at 30 minutes prior to intravenous administration of 5 to 6 mCi of 99mTc-
cis-sulfur colloid (2 to 12 micron particle size, CIS-US, Inc., Bedford, MA) for SPECT
(15-18). SPECT studies were performed at the two clinical sites and data transferred to UC
Irvine for processing (JCH, NM). Perfused hepatic mass (PHM) calculated from these
images quantified the relative distribution of sulfur colloid between liver, spleen and bone
marrow. Volumes of liver and spleen were also determined (16-20).
Organ volumes and rates of hepatic regeneration were measured by both CT and SPECT
liver-spleen scan.
Volumes from CT/MRI—CT studies and SPECT liver-spleen scan were performed on
different days. Liver and spleen volumes were determined from the standard CT software
algorithms used by the Radiology Departments at participating clinical sites.
Volumes from SPECT—Liver and spleen volumes were also calculated from the SPECT
reconstruction of images using the method of Hoefs (16-20). Volume was derived from total
counts in liver and spleen from regions of interest around the summarized transaxial image,
a representative organ concentration from a single transaxial slice, and dividing the total
hepatic or splenic counts by a representative concentration.
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Hepatic regeneration rates were defined by ΔV/Δt, from both CT and SPECT, where ΔV
was the change in hepatic volume between consecutive time points and Δt the time interval.
Baseline (B) volume was the liver volume measured prior to donation. Remnant liver
volume on the day of donation (T0) was determined from baseline CT by subtracting the
estimated right lobe graft from total liver. For SPECT, we assumed the same proportionate
size of remnant relative to baseline as was estimated from CT. Regeneration rates were
determined for the intervals from T0 to T1, T1 to T2, and T2 to T3.
Clearance tests were expressed relative to body size (per kg) or liver size (per L liver).
Changes in hepatic metabolism (microsomal function) were estimated from the serial
changes in caffeine clearance (CYP1A2) and the erythromycin breath test (CYP3A4).
Changes in total hepatic blood flow were estimated from the serial changes in galactose
elimination capacity, clearance of intravenously-administered 24-13C cholate, and SPECT
liver-spleen scan. Alteration of the portal circulation was assessed by the changes from
baseline in clearance of orally-administered 2,2,4,4-2H cholate, cholate shunt, PHM from
SPECT liver spleen scan, platelet count, and spleen volume.
Statistical Analyses
Results are expressed as means, standard deviations, and ranges. Differences between
baseline and post-donation results at T1, T2, and T3, and differences between post-baseline
time points, were compared using 2-sided paired t-tests. To test the relationship between
platelet counts and spleen size, we used both linear regression and mixed model regression
with subjects as random effects. Statistical analyses were performed at the Data
Coordinating Center for A2ALL (University of Michigan) using SAS release 9.2 (SAS
Institute, Cary, NC).
RESULTS
Twelve donors were studied at baseline (B); eight were retested at 11±3 days (T1), ten at
91±9 days (T2), and ten at 185±17 (T3) days after surgery. The mean age was 38 years
(range 21 to 54 years), body mass index (BMI) 25.2±2.8, sex 4M:8F, and 10 were white.
Standard Laboratory Tests
Table 1 displays the changes in routine laboratory tests over time after donation. All
laboratory values were normal at baseline. At T1, bilirubin, INR, and ALT were higher and
albumin lower than baseline values. By T2, these tests were trending toward baseline and at
T3, all had returned to baseline values.
Total Liver versus Perfused Liver Volume
Volumes by CT are larger than those measured by SPECT. Linear regression through the
origin of CT versus SPECT volumes, using data from all time points, indicated that liver
volumes by CT/MRI were approximately 22% larger (slope 1.22, r = 0.93, p<0.0001) and
spleen volumes 4% larger when compared with SPECT (slope 1.04, r = 0.95, p<0.0001).
Ratios of perfused liver volume (by SPECT) to total liver volume (by CT) were constant
during regeneration (0.84 to 0.86), although slightly greater than the ratio at baseline (0.78).
Regeneration Rates
Liver volumes at each time point (mL and mL/kg), reconstitution of baseline volume (Vt/
Vpre-donation), and rates of regeneration (mL kg-1 d-1) are given in Table 2. The relative
changes in these parameters during regeneration were similar between CT and SPECT. Total
liver volumes by CT at each time point (T0 through T3), relative to pre-donation volumes,
are shown for each donor in Figure 2, Panel A.
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There were at least two phases of regeneration – a rapid early phase during the first 2 weeks
and a slower later phase after the first 2 weeks. Based on CT, regeneration rates were
0.60±0.22 mL kg-1d-1 from T0 to T1, 0.05±0.02 mL kg-1d-1 from T1 to T2, and 0.01±0.01
mL kg-1d-1 from T2 to T3 (Table 2). Based on SPECT, regeneration rates were similar:
0.54±0.20 mLkg-1d-1 from T0 to T1, 0.04±0.01 mL kg-1d-1 from T1 to T2, and 0.01±0.02
mL kg-1d-1 from T2 to T3 (Table 2).
Approximately two-thirds of total hepatic regeneration occurred within the first 2 weeks
after donation, and there was minimal regeneration after 3 months. At T3, approximately 6
months after donation, liver volumes were 84±7% of baseline by CT and 92±13% of
baseline by SPECT (Table 2).
Hepatic Metabolism
Changes in hepatic metabolism from pre-donation baseline are shown in Table 3. Total
clearances of caffeine and erythromycin were slightly lower than baseline at T1; and slightly
greater than baseline by T2 and T3. After adjusting for liver volume, clearances of caffeine
and erythromycin were increased above baseline at T1, and this increase persisted through
T2 and T3. However, none of these changes in metabolism were statistically significant.
Hepatic Blood Flow
Total clearances of galactose, intravenous cholate, and SPECT, and calculated total hepatic
blood flow are displayed in Table 4. These tests reflect the total blood flow to the remnant.
At T1, total clearance of galactose (GEC) was 0.88±0.15 of pre-donation baseline
(p=0.0681), cholate after intravenous administration (CA Cliv) 0.75±0.07 of baseline
(p=0.0001), and 99mTc-cis-sulfur colloid (SPECT) 0.84±0.08 of baseline (p=0.002). Total
hepatic blood flow had decreased to 0.83±0.19 of baseline (p=0.056). Thus, by three very
different methods (GEC, dual cholate clearance, and SPECT) we demonstrated, unadjusted
for liver volume, a consistent moderate decrease in total clearance and hepatic blood flow at
T1.
Although the total clearances of flow-dependent compounds were reduced at T1, clearances
adjusted for liver volume, expressed per L liver, were increased at T1 (Table 4). Clearances
per L liver of galactose, intravenous cholate, and 99mTc-cis-sulfur colloid (estimated change
in HBF) were all increased above baseline. These findings suggest that the early rapid phase
of regeneration is associated with enhanced blood flow per unit of regenerating liver.
Orally-administered cholate is delivered to the portal circulation after its absorption from the
intestine – changes in the clearance of orally-administered cholate reflect changes in
clearance from the portal circulation. Like intravenous cholate, total clearance of orally-
administered cholate is decreased at T1, reflecting the reduced hepatic mass. But, unlike
intravenous cholate, clearance per L liver of orally-administered cholate did not increase
above baseline at T1 (Table 5). The selective increase in clearance per L liver of
intravenously-administered cholate, is consistent with selective enhancement of hepatic
arterial flow during the early phase of regeneration.
First Pass Uptake of Cholate
We estimated first-pass uptake of cholate from the fraction of the oral dose escaping hepatic
extraction, corrected for the administered dose of cholate and normalized to liver volume. At
T1, during the period of rapid regeneration, we found a significant increase in cholate uptake
(B vs. T1, mg/L liver: 21±5 vs. 31±9, p=0.017). Cholate uptake at T2 (25±4, p=0.034) and
T3 (24±6, p=0.058) approached baseline values.
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Alteration of the Portal Circulation
Several of our test results suggested that the portal circulation is altered after right lobe
donation (Table 5). At T1, the total clearance of orally-administered cholate decreased
(p=0.0006), cholate shunt increased (p=0.03), and platelet count decreased (p=0.07). These
changes persisted at T2, but, except for platelet count, trended toward normal by T3.
Paralleling the changes in platelet count, spleen volumes by both CT and SPECT increased
by T1. Spleen volume did not increase further, declined slightly, but remained above
baseline throughout (Figure 2, Panel B and Table 5). By T3, 6 months after donation, CT
spleen volume remained at 127±17% of baseline (p=0.0009) and SPECT spleen volume
remained at 150% of baseline (p=0.015). Platelet count at T1 was 14% lower than baseline
and remained decreased through T3 (Table 5). Platelet count was inversely related to spleen
volume (Figure 3). This relationship was significant both unadjusted (p=0.0001) or adjusted
(p=0.0018) for subject effects with a mixed model.
DISCUSSION
This prospective study examined the longitudinal changes in multiple hepatic functions after
donation of the right hepatic lobe by living donors, and uniquely related functional changes
to the regeneration of the left lobe remnant. Ten of the 12 donors we studied had an
uncomplicated post-operative course as indicated by standard laboratory tests and lack of
clinical complications. For the two with complications, one had a Grade 2 urinary tract
infection, and the other had a Grade 1 pleural effusion and a Grade 2 wound infection, all in
the first month post-donation. Thus, our results of hepatic imaging, volume determinations,
and function testing may likely apply to other donors undergoing a right hepatic lobectomy
with an uncomplicated or modestly complicated course.
We observed differences in liver volumes related to the differences in imaging between CT
and SPECT. CT images include all structures within the region of interest, including
vascular, connective tissue, and biliary structures. SPECT images are based on phagocytosis
of 99mTc-cis-sulfur colloid by the reticuloendothelial system and exclude nonparenchymal
structures. The 22% lower volume measured by SPECT likely reflects its selectivity for
parenchyma and the perfused hepatic mass.
Rates of regeneration varied with time following hepatic lobectomy. After lobectomy, the
residual left lobe remnant was 31% of baseline hepatic volume by CT/MRI. In the first 2
weeks post-donation, hepatic volume nearly doubled, and regeneration rate was 0.60 mL d-1
kg-1 body weight by CT/MRI and 0.54 mL d-1 kg-1 body weight by SPECT. Regeneration
slowed dramatically after the first 2 weeks. During the following approximate 3 months,
regeneration was only 0.05 mL d-1 kg-1 body weight by CT/MRI and 0.04 mL d-1 kg-1 body
weight by SPECT. Regeneration rate was even slower between 3 (T2) and 6 months (T3).
Consistent with other studies (6-9), hepatic regeneration in donors was incomplete. At 6
months post-donation, donors achieved only 84% (CT/MRI) to 92% (SPECT) of their
baseline hepatic volume. The dramatic differences in regeneration rates between time
intervals suggests that factors regulating hepatic growth and, ultimately, final liver volume
must vary considerably between the early and later phases of regeneration.
The rapid early phase of rapid hepatic regeneration, from baseline to T1, was associated
primarily with two functional changes – enhancement of hepatic blood flow per gram of
hepatic tissue and increase in the hepatic uptake of cholate. Naturally, the total hepatic blood
flow must decrease with removal of 60% of hepatic tissue, but the liver compensates by
increasing local flow. Hepatic blood flow per L liver was assessed by three independent
measurements that indicated a ~30% to 50% increase in tissue blood flow. Thus, the blood
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flow per L tissue increased helping to preserve blood flow dependent hepatic function and
partially compensate for the decrease in total hepatic mass.
In contrast to the increase in hepatic flow per L liver, the clearance of orally-administered
cholate per L liver, a marker of portal inflow, did not change. Taken together, these
observations suggest that the enhancement of hepatic blood flow is likely related to selective
recruitment of oxygen-rich hepatic arterial inflow. The importance of arterial perfusion in
hepatic regeneration was emphasized recently in a rat model of ischemic injury (21). In the
latter model, hepatic arterial perfusion determined not only the extent of hepatic necrosis but
also the formation of vascularized sinusoidal channels and parenchymal recovery.
Another unique finding of our study was selective enhancement of hepatic uptake of orally-
administered cholate during early rapid hepatic regeneration. In animal models, activation of
the primary nuclear bile acid receptor farnesoid X receptor (FXR), by the hepatic flux of bile
acids accelerates regeneration and inhibits genes of metabolism (22-24). Thus, it is of
interest that we measured a specific increase in hepatic uptake of cholate during the early
rapid phase of hepatic regeneration. We speculate that enhanced cholate uptake during the
early phase of regeneration in living donors supports a role for bile acids in the regulation of
human hepatic regeneration.
We did not observe statistically significant changes in the clearance or metabolism of two
substrates of the cytochrome P450 system, caffeine and erythromycin. The immediate effect
of hepatic resection is reduction in total hepatic metabolic capacity (25). Our results
indicated that by 11±3 days post-donation, hepatic metabolic capacity had returned toward
baseline and the metabolism of both caffeine and erythromycin per L liver had increased –
consistent with compensatory up-regulation of hepatic cytochrome P450 enzymes. A study
examining the acute phase response of cytochrome P450 enzymes after LDLT found early
reduction at day 3-4 in EBT with a return to near baseline around day 10 (26). Nonetheless,
in the first several days post-donation, it is likely that donors have a reduced total metabolic
capacity due to loss of hepatocyte mass and the immediate regenerative process (22-25). A
clinical point worth emphasizing is that dosing of medications cleared by hepatic
metabolism should be adjusted downward to avoid excessive accumulation and toxicity
during the first 1 to 2 weeks after donor hepatectomy.
An important observation of our study with potential clinical implications was evidence
pointing to an alteration of the portal circulation. Cholate shunt is a real-time measure of
events in the portal circulation. There was an initial perturbation of portal circulation with
increased cholate shunt which then trended toward normal by T2 and was at or near baseline
by T3. Other findings indicated a persistently altered portal circulation. Spleen volume
increased by T1, trended downward by T2 and T3, but remained significantly above baseline
at T3. The increase in spleen size was associated with decreased platelet count – indeed we
found a significant inverse correlation of platelet count to spleen volume.
Others have also noted a relationship between platelet count and spleen size after living
donation (25,27,28). In these studies, the reduction in platelet count was associated with
normal or elevated levels of thrombopoeitin (29). These findings and our results are
consistent with hypersplenism from persistence of an altered portal circulation and portal
hypertension and suggests that long-term follow-up of donors and evaluation for
manifestations of an altered portal circulation or portal hypertension may be warranted.
We conclude that there are at least two phases of hepatic regeneration. The early rapid phase
of regeneration lasts for 2 weeks, accounts for two-thirds of total regeneration, and is
associated with recruitment of hepatic arterial inflow and enhanced uptake of bile acids.
Right hepatic lobectomy alters the portal circulation, some of the changes reverse but others
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persist. Although the clinical implications of these findings are unknown, further long-term
studies of the portal circulation of donors may be warranted.
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Figure 1. Example of clearances of cholates before and after donation
This figure displays the clearance curves for intravenously- (solid line) and orally-(dashed
line) administered cholate isotopes in a single donor at baseline, prior to donation (upper
Panel) and at T1 after donation (lower Panel). The increase in systemic concentrations of the
orally-administered [2,2,4,4-D] cholate reflects the altered portal circulation and reduced
hepatocyte mass after resection.
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Figure 2. Liver and spleen volume ratios (compared with baseline pre-donation) by time since
donation
Panel A. Liver volumes relative to the volume of the liver at baseline prior to donation are
shown for each donor (n=10). Panel B. Spleen volumes relative to the volume of the spleen
at baseline prior to donation are shown for each donor (n=10).
Everson et al. Page 14













Figure 3. Platelet count and spleen volume per kg body weight before and after donation
The relationship of platelet count to spleen volume is shown with the cutoff for normal
platelet count at 150 μL-1. Results for studies performed at baseline, and at T1, T2, and T3
after donation are indicated by separate markers. In general, regardless of study period, there
was an inverse relationship of platelet count to spleen volume.
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Table 1
Laboratory values before and after donation





















































Tests are based on post-donation sample sizes, which assured data at both time points.
*
P-values are from two-sided paired t-tests comparing post-donation with pre-donation values.
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